MSB 2.17% $1.13 mesoblast limited

Ann: Change in substantial holding, page-65

  1. 641 Posts.
    lightbulb Created with Sketch. 96
    Mesoblast likely to raise cash after FDA setbackThe stem cell-focused biotech has been rebuffed again by the US Food and Drug Administration, hitting its shareholder hard, including billionaire Melbourne investor Alex Waislitz.



    Source: https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fcompanies%2Fmesoblast-raises-an-extra-605m-still-has-alex-waislitzs-support-who-concedes-its-been-a-long-journey%2Fnews-story%2Fc8be3e464d46c6016dcca96b261b68ee&memtype=anonymous&mode=premium&v21=dynamic-high-test-score&V21spcbehaviour=appendend
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.